CAIAFFA, MARIA FILOMENA
 Distribuzione geografica
Continente #
NA - Nord America 1.171
EU - Europa 599
AS - Asia 253
Continente sconosciuto - Info sul continente non disponibili 2
AF - Africa 1
OC - Oceania 1
Totale 2.027
Nazione #
US - Stati Uniti d'America 1.170
CN - Cina 189
DE - Germania 172
SE - Svezia 165
IT - Italia 115
SG - Singapore 53
GB - Regno Unito 47
RU - Federazione Russa 46
FI - Finlandia 15
RS - Serbia 9
FR - Francia 8
IN - India 6
BE - Belgio 5
PL - Polonia 4
IE - Irlanda 3
CZ - Repubblica Ceca 2
EU - Europa 2
LT - Lituania 2
NL - Olanda 2
VN - Vietnam 2
AM - Armenia 1
AT - Austria 1
AZ - Azerbaigian 1
CA - Canada 1
CH - Svizzera 1
DK - Danimarca 1
IM - Isola di Man 1
JP - Giappone 1
NZ - Nuova Zelanda 1
UG - Uganda 1
Totale 2.027
Città #
Chandler 161
Ashburn 156
Nyköping 131
Fairfield 107
New York 52
Houston 50
Beijing 49
Cambridge 48
Seattle 48
Dearborn 44
Woodbridge 40
Singapore 37
Nanjing 35
Wilmington 35
Lawrence 32
Roxbury 30
Bari 25
Des Moines 24
Redwood City 22
Ann Arbor 21
Brooklyn 20
Helsinki 14
Shenyang 13
Boardman 12
Nanchang 10
Belgrade 9
Inglewood 8
Santa Clara 8
Changsha 7
Jinan 7
Munich 7
San Diego 7
Guangzhou 6
Milan 6
Brussels 5
Hebei 5
San Francisco 5
Bolzano 4
Jiaxing 4
Kunming 4
Paris 4
Pune 4
Bitonto 3
Dublin 3
Hangzhou 3
Hefei 3
Jacksonville 3
Los Angeles 3
Nürnberg 3
Princeton 3
Taranto 3
Tianjin 3
Acquaviva delle Fonti 2
Cerignola 2
Chengdu 2
Cutrofiano 2
Fuzhou 2
London 2
Massafra 2
Mumbai 2
Nardò 2
Ningbo 2
Nuremberg 2
Olomouc 2
Shanghai 2
Shaoxing 2
Shenzhen 2
Washington 2
Wuhan 2
Acton 1
Amsterdam 1
Arzano 1
Auckland 1
Belpasso 1
Chenzhou 1
Chicago 1
Chiswick 1
Chongqing 1
Clifton 1
Dong Ket 1
Douglas 1
Edinburgh 1
Frosinone 1
Ho Chi Minh City 1
Jinhua 1
Kampala 1
Lecce 1
Lugano 1
Melendugno 1
Miami 1
Moscow 1
Mountain View 1
Naples 1
Napoli 1
Niva 1
Norwalk 1
Quanzhou 1
Reggio Calabria 1
Rogliano 1
Rome 1
Totale 1.411
Nome #
A 13-year real-life study on efficacy, safety and biological effects of Vespula venom immunotherapy 108
Wasp immunotherapy induced long-term and IgG4-independent protection 87
Test di proliferazione linfocitaria nella diagnosi delle reazioni ritardate a farmaci 81
Cost-effectiveness of grass pollen allergen immunotherapy in adults 78
L'allergia alimentare della Dieta Mediterranea 75
null 74
Allergia al latte. Studio sulla risposta IgE-mediata in vivo verso frazioni proteiche di latte di capra Garganica 73
Studi su Omalizumab nella terapia dell'asma severo. Valutazione degli effetti sulla risposta immunologica IgE in vivo. Valutazione della tollerabilità. 72
null 72
null 71
null 68
Omalizumab in long-term treatment of refractory chronic spontaneus urticaria:effects of discontinuation 67
null 64
Terapia dell'asma severo con omalizumab: uno studio real life in 51 pazienti. 63
Desensitization in Iron Product Allergy 63
null 60
Omalizumab nel trattamento dell'allergia alimentare 57
Long-term treatment of refractory severe chronic urticaria by omalizumab: analysis of two cases 55
Fennel (Foeniculum vulgare) allergy. 55
Leukotriene biosynthesis inhibition and direct 5-lipoxygenase (5-LO) non competitive inhibition by the Cys-LT1 receptor antagonists montelukast 53
Novel inhibitory effect on 5-lipoxygenase by the anti-asthma drug montelukast 50
Planned omalizumab discontinuation in CSU management as a sustainable strategy: A 2-year real-life study 47
Omalizumab nell'orticaria cronica spontanea: uno studio real-life su 14 pazienti 44
La disfunzione psicosomatica delle corde vocali 44
Benralizumab improves patient reported outcomes and functional parameters in difficult-to-treat patients with severe asthma: Data from a real-life cohort 43
Fennel (Phoeniculum vulgare): a major allergen of the Mediterranean Diet 39
Composizione pollinica dell'atmosfera di Barletta 39
Five-lipoxygenase/leukotriene pathway inhibition by caffeic acid phenetyl ester, caffeic acid and chlorogenic acid, natural products with anti-oxidant and anti-inflammatory properties 39
The lymphocyte proliferation test (LPT) in the diagnosis of critical cases of delayed drug allergy. 39
Sensitivity and specificity of new Vespa crabro allergen extract in patients with anaphylaxis to V. crabro. 36
A desensitization protocol for delayed allergy to cytarabine: Analysis of two cases 35
Duration of chronic spontaneous urticaria remission after omalizumab discontinuation: A long-term observational study 33
Safety of measles, mumps, and rubella vaccine in egg allergy: in vivo and in vitro management 30
Recognition of novel Mediterranean food allergens:allergy to artichoke 28
Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysis 26
Efficacy and safety of allergen immunotherapy in patients with allergy to molds: A systematic review 24
Importance of Specific IgE/Total IgE Ratio in Disambiguating Amoxicillin Allergy Diagnosis in a Real-Life Setting 24
Rapid desensitization for brentuximab vedotin (Adceteris®) allergy: A case report 21
Long-term treatment of refractory severe urticaria by omalizumab: analysis of two cases. 20
Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS) 13
SANI-Severe Asthma Network in Italy: A way forward to monitor severe asthma 10
Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps 8
Features of severe asthma response to anti-IL5/IL5r therapies: identikit of clinical remission 6
Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study 5
Real-world characteristics of "super-responders" to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis 2
Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis 1
Cluster Analysis Identifies Patients With Severe Eosinophilic Asthma Who Achieve Super-Response and Remission With Mepolizumab 1
Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M Study 1
Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus 1
Totale 2.105
Categoria #
all - tutte 10.564
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.564


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020254 0 0 0 0 16 47 43 21 17 43 43 24
2020/2021255 13 27 16 31 21 38 24 24 12 20 13 16
2021/2022260 5 22 3 3 11 33 8 15 6 14 39 101
2022/2023437 45 103 38 12 30 62 7 30 86 1 15 8
2023/2024275 11 29 12 17 11 114 30 22 5 2 2 20
2024/2025153 50 5 71 16 11 0 0 0 0 0 0 0
Totale 2.105